Related Experiment Video

Updated: May 15, 2026

Describing a Transcription Factor Dependent Regulation of the MicroRNA Transcriptome
07:23

Describing a Transcription Factor Dependent Regulation of the MicroRNA Transcriptome

Published on: June 15, 2016

A novel inhibitor of STAT3 homodimerization selectively suppresses STAT3 activity and malignant transformation

Xiaolei Zhang1, Ying Sun, Roberta Pireddu

  • 1Department of Drug Discovery, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33612, USA.

Cancer Research
|January 17, 2013
PubMed

Insights

A novel small molecule, S3I-1757, effectively inhibits Signal Transducer and Activator of Transcription 3 (STAT3) dimerization. This inhibition blocks cancer cell growth, migration, and invasion, offering a new therapeutic strategy.

Area of Science:

  • Molecular Biology
  • Cancer Research
  • Drug Discovery

Background:

  • Signal Transducer and Activator of Transcription 3 (STAT3) dimerization is crucial for its nuclear translocation, DNA binding, and gene regulation.
  • Hyperactivated STAT3 signaling drives malignant transformation and tumor progression in various human cancers.

Purpose of the Study:

  • To develop and characterize a small molecule inhibitor that disrupts STAT3-STAT3 dimerization.
  • To evaluate the efficacy of this inhibitor in blocking STAT3 activation and suppressing cancer cell malignant activities.

Main Methods:

  • Fluorescence polarization assays and molecular modeling to assess S3I-1757's interaction with STAT3.
  • Coimmunoprecipitation and colocalization studies in intact cancer cells to confirm inhibition of STAT3 dimerization and EGFR binding.
  • Assessment of S3I-1757's effects on STAT3 phosphorylation, nuclear translocation, DNA binding, and target gene expression.
  • Evaluation of S3I-1757's impact on cancer cell proliferation, migration, and invasion.

Main Results:

  • S3I-1757 directly interacts with the STAT3 SH2 domain, inhibiting STAT3-STAT3 dimerization and STAT3-EGFR binding.
  • S3I-1757 selectively inhibits STAT3 phosphorylation, nuclear accumulation, DNA binding, and transcriptional activity, unlike control analog S3I-1756.
  • S3I-1757 effectively suppresses anchorage-dependent and -independent growth, migration, and invasion of STAT3-dependent cancer cells.
  • A constitutively dimerized STAT3 mutant (STAT3-C) rescues cells from S3I-1757's inhibitory effects.

Conclusions:

  • S3I-1757 is a potent inhibitor of STAT3-STAT3 dimerization.
  • This compound effectively blocks STAT3 signaling pathways essential for cancer cell survival and proliferation.
  • S3I-1757 represents a promising therapeutic agent for STAT3-dependent human cancers.

More Related Videos

Merging Absolute and Relative Quantitative PCR Data to Quantify STAT3 Splice Variant Transcripts11:19

Merging Absolute and Relative Quantitative PCR Data to Quantify STAT3 Splice Variant Transcripts

Published on: October 9, 2016

Related Concept Videos

The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...